U.S. District Judge Amit Mehta ruled July 8 that the Trump administration doesn’t have the authority to issue the rule, effectively preventing the rule from taking effect July 9 as planned.
The rule was announced in May as part of President Donald Trump’s blueprint to lower prescription drug costs in the U.S.
Under the rule, drugmakers would have to include the list price of their drugs if a month’s supply cost $35 or more.
Three major drugmakers, Merck, Eli Lilly and Amgen, filed a lawsuit to block the rule on June 14, arguing that the rule would confuse customers and it violated drugmakers’ freedom of speech.
Access the full report here.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.